BiotechTube
Xgenera

Xgenera

Oxford, United Kingdom· Est.
xgenera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Xgenera is an Oxford-based private biotech founded in 2019, pivoting from its initial gene therapy focus to become a diagnostics company specializing in early cancer detection. Its core asset is the miONCO test, a multi-cancer early detection platform currently in a large-scale retrospective clinical trial. The company has secured non-dilutive grant funding and venture capital, positioning it to advance its technology through clinical validation and towards commercialization.

Oncology

Technology Platform

miONCO multi-cancer early detection (MCED) platform, a liquid biopsy test designed to detect up to 12 different cancer types from a single sample.

Opportunities

The multi-cancer early detection market is a multi-billion dollar opportunity with massive unmet need, as current screening covers only a few cancer types.
Successful validation could lead to adoption in national health screening programs and private healthcare, offering significant improvements in patient outcomes and potential cost savings for healthcare systems.

Risk Factors

Key risks include the technical challenge of achieving high sensitivity and specificity across multiple cancers, intense competition from well-funded rivals like Grail, and the uncertain regulatory and reimbursement pathways for a novel pan-cancer diagnostic test.

Competitive Landscape

Xgenera operates in the highly competitive Multi-Cancer Early Detection (MCED) space, competing against well-established players such as Grail (Illumina), Exact Sciences, and Freenome. Differentiation will require superior clinical performance data, a clear path to market access, and strategic partnerships.

More companies in United Kingdom →